With over 25 years of experience in the development and production of the ophthalmic portfolio, JGL now operates in more than 50 markets globally. It is the biggest manufacturer of ophthalmic preparations in the region, providing modern solutions for the most common eye diseases – from dry eye, a common issue linked to the modern lifestyle, to glaucoma, the “silent thief of sight” associated with ageing.
To celebrate 25 years of its ophthalmic business, and with the aim of integrating prescription and OTC ophthalmic products into a single whole, JGL has launched its “JGL, the Ophthalmology Specialist” campaign. Given that the sense of sight has a significant impact on the quality of life, JGL is committed to respecting the highest quality standards, which is also reflected in the campaign slogan “The Quality You Can See”.
As a reminder, the first JGL drug in this therapeutic class, Timalen, was launched back in 1997. An important milestone in this segment of the JGL portfolio was reached in 2010, when the company produced, registered and launched the first generic version of latanoprost in Europe – Latanox eye drops. Latanoprost is still one of the most commonly prescribed anti-glaucoma agents and the “gold standard” of its category. Latanox drops are one of JGL’s more successful products, as evidenced by the 30 million vials produced since its launch.
Over time, the company specialised in the production of sterile drops and introduced a diverse portfolio of ophthalmic products, with Vizol S at the forefront as one of JGL’s key brands.